Medicare Advantage and Medicare Prescription Drug Programs Expected to Remain Stable in 2027The Centers for Medicare & Medicaid Services (CMS) today announced significant premium savings for millions ...

CMS’s efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medicati...

This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demo...

What’s changing: Today, the CMS Innovation Center announced changes to its model portfolio to align with its statutory obligation and strategic goals.

It depends. If you’re receiving benefits from Social Security or the Railroad Retirement Board (RRB) at least four months before you turn 65, you do NOT need to sign up; you’ll automatically get Part ...

It’s quite likely that one of these popular anti-obesity medications will be selected for negotiation in the next round of Medicare’s relatively new drug price negotiation program.

This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly ...

Medicare Part D is a voluntary outpatient prescription drug benefit for people with Medicare provided through private plans, including stand-alone prescription drug plans and Medicare Advantage plans ...

Enhanced Affordable Care Act (ACA) subsidies lower premium payments for ACA Marketplace coverage by boosting existing ACA subsidies and making some people newly eligible. Enrollees across incomes bene...